Literature DB >> 31738367

Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

Stella A Glasmacher1, Charis Wong2,3,4, Iona E Pearson1, Suvankar Pal2,3,4.   

Abstract

Importance: The c9orf72 repeat expansion (c9 or c9orf72RE) confers a survival disadvantage in amyotrophic lateral sclerosis (ALS); its effect on prognosis in frontotemporal dementia (FTD) remains uncertain. Data on prognostic factors in c9orf72RE disorders could inform patient care, genetic counseling, and trial design. Objective: To examine prognostic factors in c9ALS, c9FTD, c9ALS-FTD, and atypical phenotypes. Data Sources: The MEDLINE, Embase, Amed, ProQuest, PsychINFO, CINAHL, and LILACS databases were searched between January 2011 and January 2019. Keywords used were c9orf72 and chromosome 9 open reading frame 72. Reference lists, citations of eligible studies, and review articles were also searched by hand. Study Selection: Studies reporting disease duration for patients with a confirmed c9orf72RE and a neurological and/or psychiatric disorder were included. A second author independently reviewed studies classified as irrelevant by the first author. Analysis began in January 2019. Data Extraction and Synthesis: Data were extracted by 1 author; a further author independently extracted 10% of data. Data were synthesized in univariate and multivariable Cox regression and are displayed as hazard ratios (HR) and 95% confidence intervals. Main Outcomes and Measures: Survival after symptom onset.
Results: Overall, 206 studies reporting on 1060 patients were included from 2878 publications identified (c9ALS: n = 455; c9FTD: n = 296; c9ALS-FTD: n = 198; atypical phenotypes: n = 111); 197 duplicate cases were excluded. The median (95% CI) survival (in years) differed significantly between patients with c9ALS (2.8 [2.67-3.00]), c9FTD (9.0 [8.09-9.91]), and c9ALS-FTD (3.0 [2.73-3.27]); survival in atypical phenotypes varied substantially. Older age at onset was associated with shorter survival in c9ALS (HR, 1.03; 95% CI, 1.02-1.04; P < .001), c9FTD (HR, 1.04; 95% CI, 1.02-1.06; P < .001), and c9ALS-FTD (HR, 1.02; 95% CI, 1.004-1.04; P = .016). Bulbar onset was associated with shorter survival in c9ALS (HR, 1.64; 95% CI, 1.27-2.08; P < .001). Age at onset and bulbar onset ALS remained significant in multivariable regression including variables indicating potential diagnostic ascertainment bias, selection bias, and reporting bias. Family history, sex, study continent, FTD subtype, or the presence of additional pathogenic sequence variants were not significantly associated with survival. Clinical phenotypes in patients with neuropathologically confirmed frontotemporal lobar degeneration-TDP-43, motor neuron disease-TDP-43 and frontotemporal lobar degeneration-motor neuron disease-TDP-43 were heterogenous and impacted on survival. Conclusions and Relevance: Several factors associated with survival in c9orf72RE disorders were identified. The inherent limitations of our methodological approach must be considered; nonetheless, the reported prognostic factors were not significantly associated with the bias indicators examined.

Entities:  

Year:  2020        PMID: 31738367      PMCID: PMC6865318          DOI: 10.1001/jamaneurol.2019.3924

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  64 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

3.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.

Authors:  Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-03-18       Impact factor: 17.088

4.  C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis.

Authors:  Gabriel Miltenberger-Miltenyi; Vasco A Conceição; Marta Gromicho; Ana Catarina Pronto-Laborinho; Susana Pinto; Peter M Andersen; Mamede de Carvalho
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-04-16       Impact factor: 10.154

5.  Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes.

Authors:  Janet Cady; Peggy Allred; Taha Bali; Alan Pestronk; Alison Goate; Timothy M Miller; Robi D Mitra; John Ravits; Matthew B Harms; Robert H Baloh
Journal:  Ann Neurol       Date:  2014-11-27       Impact factor: 10.422

6.  A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.

Authors:  Ilse Gijselinck; Tim Van Langenhove; Julie van der Zee; Kristel Sleegers; Stéphanie Philtjens; Gernot Kleinberger; Jonathan Janssens; Karolien Bettens; Caroline Van Cauwenberghe; Sandra Pereson; Sebastiaan Engelborghs; Anne Sieben; Peter De Jonghe; Rik Vandenberghe; Patrick Santens; Jan De Bleecker; Githa Maes; Veerle Bäumer; Lubina Dillen; Geert Joris; Ivy Cuijt; Ellen Corsmit; Ellen Elinck; Jasper Van Dongen; Steven Vermeulen; Marleen Van den Broeck; Carolien Vaerenberg; Maria Mattheijssens; Karin Peeters; Wim Robberecht; Patrick Cras; Jean-Jacques Martin; Peter P De Deyn; Marc Cruts; Christine Van Broeckhoven
Journal:  Lancet Neurol       Date:  2011-12-07       Impact factor: 44.182

7.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

8.  Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration.

Authors:  EunRan Suh; Edward B Lee; Donald Neal; Elisabeth M Wood; Jon B Toledo; Lior Rennert; David J Irwin; Corey T McMillan; Bryan Krock; Lauren B Elman; Leo F McCluskey; Murray Grossman; Sharon X Xie; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Acta Neuropathol       Date:  2015-05-29       Impact factor: 17.088

9.  Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene.

Authors:  Marka van Blitterswijk; Bianca Mullen; Aleksandra Wojtas; Michael G Heckman; Nancy N Diehl; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Mol Neurodegener       Date:  2014-09-20       Impact factor: 14.195

10.  Investigation of c9orf72 in 4 neurodegenerative disorders.

Authors:  Zhengrui Xi; Lorne Zinman; Yakov Grinberg; Danielle Moreno; Christine Sato; Juan M Bilbao; Mahdi Ghani; Isabel Hernández; Agustín Ruiz; Mercè Boada; Francisco J Morón; Anthony E Lang; Connie Marras; Amalia Bruni; Rosanna Colao; Raffaele G Maletta; Gianfranco Puccio; Innocenzo Rainero; Lorenzo Pinessi; Daniela Galimberti; Karen E Morrison; Catriona Moorby; Joanne D Stockton; Mario Masellis; Sandra E Black; Lili-Naz Hazrati; Yan Liang; Jan van Haersma de With; Luis Fornazzari; Roque Villagra; Ricardo Rojas-Garcia; Jordi Clarimón; Richard Mayeux; Janice Robertson; Peter St George-Hyslop; Ekaterina Rogaeva
Journal:  Arch Neurol       Date:  2012-12
View more
  8 in total

1.  Temporal order of clinical and biomarker changes in familial frontotemporal dementia.

Authors:  Adam M Staffaroni; Melanie Quintana; Barbara Wendelberger; Hilary W Heuer; Lucy L Russell; Yann Cobigo; Amy Wolf; Sheng-Yang Matt Goh; Leonard Petrucelli; Tania F Gendron; Carolin Heller; Annie L Clark; Jack Carson Taylor; Amy Wise; Elise Ong; Leah Forsberg; Danielle Brushaber; Julio C Rojas; Lawren VandeVrede; Peter Ljubenkov; Joel Kramer; Kaitlin B Casaletto; Brian Appleby; Yvette Bordelon; Hugo Botha; Bradford C Dickerson; Kimiko Domoto-Reilly; Julie A Fields; Tatiana Foroud; Ralitza Gavrilova; Daniel Geschwind; Nupur Ghoshal; Jill Goldman; Jonathon Graff-Radford; Neill Graff-Radford; Murray Grossman; Matthew G H Hall; Ging-Yuek Hsiung; Edward D Huey; David Irwin; David T Jones; Kejal Kantarci; Daniel Kaufer; David Knopman; Walter Kremers; Argentina Lario Lago; Maria I Lapid; Irene Litvan; Diane Lucente; Ian R Mackenzie; Mario F Mendez; Carly Mester; Bruce L Miller; Chiadi U Onyike; Rosa Rademakers; Vijay K Ramanan; Eliana Marisa Ramos; Meghana Rao; Katya Rascovsky; Katherine P Rankin; Erik D Roberson; Rodolfo Savica; M Carmela Tartaglia; Sandra Weintraub; Bonnie Wong; David M Cash; Arabella Bouzigues; Imogen J Swift; Georgia Peakman; Martina Bocchetta; Emily G Todd; Rhian S Convery; James B Rowe; Barbara Borroni; Daniela Galimberti; Pietro Tiraboschi; Mario Masellis; Elizabeth Finger; John C van Swieten; Harro Seelaar; Lize C Jiskoot; Sandro Sorbi; Chris R Butler; Caroline Graff; Alexander Gerhard; Tobias Langheinrich; Robert Laforce; Raquel Sanchez-Valle; Alexandre de Mendonça; Fermin Moreno; Matthis Synofzik; Rik Vandenberghe; Simon Ducharme; Isabelle Le Ber; Johannes Levin; Adrian Danek; Markus Otto; Florence Pasquier; Isabel Santana; John Kornak; Bradley F Boeve; Howard J Rosen; Jonathan D Rohrer; Adam L Boxer
Journal:  Nat Med       Date:  2022-09-22       Impact factor: 87.241

Review 2.  C9orf72-Related Neurodegenerative Diseases: From Clinical Diagnosis to Therapeutic Strategies.

Authors:  Stefania Zampatti; Cristina Peconi; Rosa Campopiano; Stefano Gambardella; Carlo Caltagirone; Emiliano Giardina
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

Review 3.  An update on the neurological short tandem repeat expansion disorders and the emergence of long-read sequencing diagnostics.

Authors:  Sanjog R Chintalaphani; Sandy S Pineda; Ira W Deveson; Kishore R Kumar
Journal:  Acta Neuropathol Commun       Date:  2021-05-25       Impact factor: 7.801

Review 4.  Genetics and Sex in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS): Is There a Link?

Authors:  Francesca Trojsi; Giulia D'Alvano; Simona Bonavita; Gioacchino Tedeschi
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

Review 5.  Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions.

Authors:  Emma L van der Ende; Jazmyne L Jackson; Marka van Blitterswijk; John C Van Swieten; Adrianna White; Harro Seelaar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-01-15       Impact factor: 10.154

6.  ALS in Finland: Major Genetic Variants and Clinical Characteristics of Patients With and Without the C9orf72 Hexanucleotide Repeat Expansion.

Authors:  Hannu Laaksovirta; Jyrki Launes; Lilja Jansson; Bryan J Traynor; Karri Kaivola; Pentti J Tienari
Journal:  Neurol Genet       Date:  2022-03-14

7.  Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing.

Authors:  Igor Stevanovski; Sanjog R Chintalaphani; Hasindu Gamaarachchi; James M Ferguson; Sandy S Pineda; Carolin K Scriba; Michel Tchan; Victor Fung; Karl Ng; Andrea Cortese; Henry Houlden; Carol Dobson-Stone; Lauren Fitzpatrick; Glenda Halliday; Gianina Ravenscroft; Mark R Davis; Nigel G Laing; Avi Fellner; Marina Kennerson; Kishore R Kumar; Ira W Deveson
Journal:  Sci Adv       Date:  2022-03-04       Impact factor: 14.136

8.  The repeat length of C9orf72 is associated with the survival of amyotrophic lateral sclerosis patients without C9orf72 pathological expansions.

Authors:  Lu Tang; Lu Chen; Xiaolu Liu; Ji He; Yan Ma; Nan Zhang; Dongsheng Fan
Journal:  Front Neurol       Date:  2022-08-03       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.